SNDX

Syndax Pharmaceuticals, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Metzger Michael ADirector, Officer: Chief Executive Officer
$130k6.8k shares
SellJun 1, 2026
$18.99
--
Goldan Keith A.Chief Financial Officer
$22k1.2k shares
SellJun 1, 2026
$18.99
--
Metzger Michael ADirector, Officer: Chief Executive Officer
$361k17.2k shares
SellFeb 9, 2026
$21.03
--
Goldan Keith A.Chief Financial Officer
$72k3.4k shares
SellFeb 9, 2026
$21.03
--
Metzger Michael ADirector, Officer: Chief Executive Officer
$153k7.4k shares
SellFeb 6, 2026
$20.62
--
Goldan Keith A.Chief Financial Officer
$43k2.1k shares
SellFeb 6, 2026
$20.62
--

News

seekingalpha.comSyndax Pharmaceuticals: The Duration Expansion Story Is Being Underpricedseekingalpha.comJun 11globenewswire.comSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026globenewswire.comJun 11globenewswire.comSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncologyglobenewswire.comJun 11seekingalpha.comSyndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.comJun 10seekingalpha.comSyndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8